This prospectus relates to the proposed resale or other disposition from time to time of up to 1,231,988 shares of Jaguar Health, Inc. common stock, $0.0001 par value per share, issuable upon conversion of 18,479,826 shares of non-voting common stock held by the selling shareholder identified in this prospectus. We are not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of common stock by the selling shareholder.
The selling shareholder or its pledgees, assignees or successors-in-interest may offer and sell or otherwise dispose of the shares of common stock described in this prospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling shareholder will bear all commissions and discounts, if any, attributable to the sales of shares. We will bear all other costs, expenses and fees in connection with the registration of the shares. See "Plan of Distribution" beginning on page 10 for more information about how the selling shareholder may sell or dispose of their shares of common stock.
Our common stock is listed on the NASDAQ Capital Market, under the symbol "JAGX." On July 27, 2018, the last reported sale price of our common stock on the NASDAQ Capital Market was $0.98 per share.
Investing in our common stock involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page 7 of this prospectus under the caption "Risk Factors" and in the documents incorporated by reference into this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2018.
Recent JAGX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:33 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 12:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 10:30:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:13:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:25:44 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 11/30/2023 01:10:26 PM
- FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS • PR Newswire (Canada) • 11/15/2023 02:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:03:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 09:03:29 PM
- FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU • PR Newswire (Canada) • 09/21/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:55:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:50:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:49:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:48:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:46:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2023 08:16:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 09:27:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2023 09:00:36 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM